Can we Slow Neurodegeneration in Multiple Indications without Reducing Neurofilament Light Chain?
Time: 9:00 am
day: Conference Day Two
Details:
- Reviewing data on NFL in different neurodegenerative diseases
- Mechanisms and factors that contribute to NFL levels in biofluids
- Exploring examples of different ALS therapeutic trials where NFL was reduced with treatment response
- Does the timing of NFL reductions during trials depend upon the mechanism of action of the treatment?
- Evaluating feasibility for controlling baseline heterogeneity with NFL for more confident confirmation of efficacy
